# A Benefit Nobody Observed

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/a-benefit-nobody-observed

> A cardiology journal reports GLP-1 therapy could cut ten-year cardiovascular risk by 22% in people who have never had heart disease. Nobody in the study took the drug.

## Key points

- A modeling study in which nobody took the drug. Risk-factor changes were applied arithmetically.
- Projected 13.82% → 10.83% ten-year CVD incidence; 2.99 points absolute, 22% relative.
- It assumes the benefit flows through the five risk factors, but SELECT found it largely independent of them.
- Which could mean the estimate is too high OR too low. The direction of error is unknown.
- 2.99 points over ten years is a number needed to treat of about 33.
- The authors say it supports running a trial. That is the correct use of it.

A study in a leading cardiology journal reports that GLP-1 therapy could cut ten-year cardiovascular risk by 22% in people who have never had heart disease.[1] Nobody in it took the drug. Researchers applied the risk-factor changes from a completed trial to 200,012 people in health surveys and ran a risk equation. The assumption underneath that arithmetic is one the source trial partly contradicts.

## What was done

First, a model was fitted in 610,789 people without cardiovascular disease, predicting ten-year cardiovascular events and death from five inputs: BMI, HbA1c, systolic blood pressure, C-reactive protein, and non-HDL cholesterol.

Then that model was applied to 200,012 people from two health surveys. For each, the researchers *adjusted the five inputs* by the amounts semaglutide changed them in the SELECT trial, and recalculated the predicted risk. The difference between the two predictions is the reported benefit.

*Projected outcomes in 21,720 people with a BMI of 27 or more and a baseline ten-year risk of 7.5% or higher.[1]*

|   | Ten-year cardiovascular incidence |
| --- | --- |
| Observed | 13.82% (95% CI 11.94–15.71) |
| **Projected with treatment** | **10.83% (9.27–12.39)** |
| Absolute difference | 2.99 percentage points (2.67–3.31) |
| Relative difference | 22% |

Absolute reductions were larger in men than women, 3.14 against 2.7 percentage points, with similar relative effects. Both shrank in people who were not obese, in people at lower baseline risk, and further still once imperfect adherence was assumed.

## The assumption the source trial contradicts

> **This model works by assuming the drug’s cardiovascular benefit flows through the five risk factors it adjusts.** Change the weight, the blood pressure, the inflammation and the cholesterol, and the benefit follows. That is the entire mechanism of the calculation.

SELECT itself examined that assumption, in a prespecified analysis of its own 17,604 participants, and found the cardiovascular benefit **largely independent of weight loss**. There was no linear relationship between weight lost by week 20 and later events, and only about a third of the benefit was mediated through waist circumference. We covered it in [losing weight predicted more heart attacks](https://glpwatchdog.org/research/losing-weight-predicted-more-heart-attacks).

> In SELECT, only about a third of the cardiovascular benefit was mediated through waist circumference.

The projection could be too high, or it could as easily be too low: if most of the benefit arrives by some pathway the five factors do not capture, a model built only on those factors would miss it. The calculation is not measuring the thing it is presented as measuring, and its direction of error is unknown.

There is a second, more ordinary problem. SELECT enrolled people who *already had* cardiovascular disease. This study applies its risk-factor changes to people who do not. Whether a drug moves risk factors by the same amount in a lower-risk population is an assumption, and whether the same movement buys the same protection is another.

## The projection as a number needed to treat

Set the mechanism question aside for a moment and take the projection at face value. A 2.99 percentage point absolute reduction over ten years corresponds to a **number needed to treat of roughly 33**: treat 33 people for a decade to prevent one cardiovascular event.

That is a real and defensible figure for a preventive therapy, and it is also ten years of an expensive injection with the side effects we cover elsewhere. Whether it is worth it depends on cost, tolerability and preference, and no risk model answers that. The general case for reading absolute numbers rather than relative ones is in [how many people to treat to help one](https://glpwatchdog.org/research/how-many-people-to-treat-to-help-one).

## What the authors claim

> **To their credit, they do not overclaim.** Their conclusion is that in appropriately selected people at high risk, this therapy *may* complement existing prevention, and that the finding supports the rationale for *future randomized studies*. That is the correct reading of a modeling exercise, and it is not what a headline will do with “22% reduction.”

The value of work like this is in deciding what to test, not in deciding what to prescribe. It says a trial of these drugs for primary prevention is worth running (none has reported yet), and it says roughly how large an effect such a trial would need to be powered to detect.

## Frequently asked questions

### Do GLP-1 drugs prevent heart disease in people who have never had it?

Unknown, because no trial has reported on it yet. This study projected a 22% relative and 2.99 percentage point absolute reduction over ten years, by applying risk-factor changes from a completed trial to survey populations and running a risk equation. Nobody in it took the drug.

### Why does that matter?

Because the calculation assumes the benefit flows through the five risk factors it adjusts. The trial supplying those inputs found its cardiovascular benefit largely independent of weight loss, with only about a third mediated through waist circumference.

### Does that mean the estimate is too high?

Not necessarily. If most of the benefit arrives by a pathway those five factors do not capture, the model would understate it. The problem is that it is not measuring what it appears to, and the direction of error is unknown.

### What would the benefit be worth if the projection is right?

A 2.99 percentage point absolute reduction over ten years is a number needed to treat of roughly 33: treating 33 people for a decade to prevent one event. Whether that is worthwhile involves cost and tolerability, which no risk model addresses.

### What is the study good for?

Deciding what to test. The authors say it supports the rationale for future randomized studies, which is the correct use of a modeling exercise.

## References

1. Schrage B, Lackner MK, Hoshiyar A, et al. Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population. Journal of the American College of Cardiology. 2026. PMID: 41811277. https://pubmed.ncbi.nlm.nih.gov/41811277/

---

Cite as: GLP Watchdog, Nora Bissett, "A Benefit Nobody Observed", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/a-benefit-nobody-observed

Canonical HTML page: https://glpwatchdog.org/research/a-benefit-nobody-observed

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
